Focus: Verity Pharmaceuticals is a specialty pharmaceutical company focused on genitourinary therapies, headquartered in Ewing, NJ. The company operates a mature, revenue-generating portfolio centered on a single blockbuster asset.
Profile data last refreshed 10h ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow Verity Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship product generating 87% of company revenue; faces patent cliff with unclear timeline, representing primary near-term financial risk.
Help build intelligence for Verity Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Verity Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Secondary revenue contributor facing loss of exclusivity in May 2027; represents $1M revenue at risk.
Long-tail patent protection (LOE 2041) provides revenue stability, but Part D spending remains modest at $772K annually.
Peak-stage formulation with June 2029 LOE; overlaps with other TRELSTAR entries, indicating multiple formulation variants.
Additional TRELSTAR variant facing imminent patent loss; unclear LOE date compounds strategic uncertainty.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub